# Study of AGB101 in Mild Cognitive Impairment Due to Alzheimer's Disease

> **NCT03486938** · PHASE2,PHASE3 · COMPLETED · sponsor: **AgeneBio** · enrollment: 164 (actual)

## Conditions studied

- Mild Cognitive Impairment
- Prodromal Alzheimer's Disease

## Interventions

- **DRUG:** Placebo Oral Tablet
- **DRUG:** AGB101 220 mg tablet

## Key facts

- **NCT ID:** NCT03486938
- **Lead sponsor:** AgeneBio
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-13
- **Primary completion:** 2022-11-02
- **Final completion:** 2022-11-02
- **Target enrollment:** 164 (ACTUAL)
- **Last updated:** 2024-05-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03486938

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03486938, "Study of AGB101 in Mild Cognitive Impairment Due to Alzheimer's Disease". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03486938. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*